No Data
Domestic Innovative Drugs are once again surging towards overseas markets! Concept stocks have responded with a significant increase. Is the external authorization model the optimal choice?
① As of the time of publication, the Hang Seng Innovative Drugs Index has risen over 5%, with multiple Innovative Drugs concept stocks experiencing double-digit gains; ② In recent days, Jiangsu Hengrui Pharmaceuticals, Hepo Pharmaceutical, UNITED LAB, and other Biotech companies have issued announcements about "going abroad"; ③ Northeast Securities stated that top MNCs recognize the R&D capabilities of Chinese local companies and are more willing to assign high valuations.
Beijing Aosaikang Pharmaceutical (002755.SZ) announced long-term follow-up data of the Innovative Drug Liratinib for the treatment of non-small cell lung cancer at the 2025 Europe Lung Cancer Conference.
On March 26, Gelonghui reported that Beijing Aosaikang Pharmaceutical (002755.SZ) announced that its wholly-owned subsidiary Jiangsu Aosaikang Pharmaceutical Co., Ltd. will present long-term follow-up data on Innovative Drug Lieratinib for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFRT790M mutation at the 2025 European Lung Cancer Conference (ELCC) in poster form from March 26 to 29, 2025. Lieratinib is a novel third-generation EGFR tyrosine kinase inhibitor (TKI) that has completed the crucial Phase IIB clinical trial for EGFRT790M mutation positive NSCLC.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Osecon: 2024 Annual Results Forecast
Beijing Aosaikang Pharmaceutical (002755.SZ): Expected profit of 0.15 billion yuan to -0.195 billion yuan for the year 2024, turning losses into profits compared to the same period last year.
Gelonghui, January 22丨Beijing Aosaikang Pharmaceutical (002755.SZ) announced its earnings forecast for the 2024 fiscal year, with net income attributable to shareholders of the listed company expected to be between 0.15 billion yuan and 0.195 billion yuan, turning a profit compared to the previous year; net income excluding non-recurring gains and losses is expected to be between 0.116 billion yuan and 0.15 billion yuan; and basic EPS is expected to be between 0.17 yuan/share and 0.22 yuan/share. The company’s sales of anti-infection and chronic disease products are growing rapidly, and its revenue has achieved year-on-year growth with enhanced profitability. The company continues to analyze, evaluate, and optimize its R&D projects, focusing on promoting key advantageous products.
Beijing Aosaikang Pharmaceutical (002755.SZ): Subsidiary Qufu Nucleoside and Pyrimethamine Tablets obtained Pharmaceutical registration certificate.
On January 20, Gelonghui reported that Beijing Aosaikang Pharmaceutical (002755.SZ) announced that its wholly-owned subsidiary Jiangsu Aosaikang Pharmaceutical Co., Ltd. (hereinafter referred to as "the subsidiary") has recently received the Drug Registration Certificate approved and issued by the National Medical Products Administration for Urokinase and Tepanex tablets. Urokinase and Tepanex tablets are an oral compound nucleoside chemotherapy drug composed of Urokinase and Tepanex in a molar ratio of 1:0.5, suitable for patients who have previously undergone chemotherapy based on fluoropyrimidines, oxaliplatin, and irinotecan, as well as those who have or cannot receive anti-vascular endothelial growth factor (VEGF) treatments.
